Oncology and Technology: Electronic Patient-Reported Outcomes Across Patient Populations

Patients and care teams benefit from electronic, patient-reported outcomes. John Elliott, vice president of sales at Carevive, and Rami Elsabeh, chief product officer at DTX, spoke with Oncology and Technology to stress the importance ePROs play across patient populations.

DTX is a web-based ePRO tool that uses automated SMS surveys to connect with patients throughout their care episode. Elsabeh said this software allows for streamlined information exchange between patients and the care team.

“ePROs historically have been predominantly used more in a research capacity,” Elliott said. “That was the original case for ePROs, and it was fairly removed from any type of reimbursement. What’s really evolved is when you have major payers, and you have CMS, and you start looking at value-based reimbursement models, there is strong advocacy for ePROs.”

Because ePROs were primarily a research tool, the original focus was data collection. “Nowadays, with the increase in value-based care, reimbursement being tied more and more to quality of care versus quantity of care, and the emphasis on patient outcomes and cost-reduction methods, the ePRO systems they need to have extended capabilities,” Elsabeh said.

“What’s huge about the evolution is the integration capabilities now,” Elliott said. “So, taking it from a fairly segmented, siloed, single research population to a standard of care for a much broader patient population with actionable capabilities for the care team. That’s how you get to the improved outcomes.”

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More